(Q64957463)

1 July 2019

title

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults. (English)

1 reference

1 July 2019

pneumococcal conjugate vaccine

main subject

1 reference

Mark Atwood

1

1 reference

1 July 2019

Linda Beausoleil

2

1 reference

1 July 2019

Marie-Claude Breton

3

1 reference

1 July 2019

Craig Laferriere

4

1 reference

1 July 2019

Reiko Sato

5

1 reference

1 July 2019

Derek Weycker

6

1 reference

1 July 2019

publication date

9 May 2018

1 reference

1 July 2019

Canadian Journal of Public Health

published in

1 reference

1 July 2019

volume

109

1 reference

1 July 2019

issue

5-6

1 reference

1 July 2019

page(s)

756-768

1 reference

1 July 2019

Creative Commons Attribution 4.0 International

copyright license

start time

9 May 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.17269/s41997-018-0050-9

0 references

cites work

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

1 reference

12 December 2020

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

1 reference

12 December 2020

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

1 reference

12 December 2020

Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly.

1 reference

12 December 2020

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

12 December 2020

Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study

1 reference

12 December 2020

The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults

1 reference

12 December 2020

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

1 reference

12 December 2020

Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada

1 reference

12 December 2020

Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.

1 reference

12 December 2020

Statement on the recommended use of pneumococcal 23-valent polysaccharide vaccine in homeless persons and injection drug users. An Advisory Committee Statement (ACS)

1 reference

12 December 2020

The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine

1 reference

12 December 2020

23-valent pneumococcal polysaccharide vaccine. WHO position paper

1 reference

12 December 2020

Changing Epidemiology of Invasive Pneumococcal Disease in Canada, 1998–2007: Update from the Calgary‐Area Streptococcus pneumoniae Research (CASPER) Study

1 reference

12 December 2020

The epidemiology of invasive pneumococcal disease in British Columbia following implementation of an infant immunization program: increases in herd immunity and replacement disease.

1 reference

12 December 2020

Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine

1 reference

12 December 2020

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.

1 reference

12 December 2020

Long-term survival following pneumococcal pneumonia

1 reference

12 December 2020

Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia

1 reference

12 December 2020

Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults

1 reference

12 December 2020

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

1 reference

12 December 2020

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

1 reference

12 December 2020

U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination

1 reference

12 December 2020

Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.

1 reference

12 December 2020

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.

1 reference

12 December 2020

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012

1 reference

12 December 2020

Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort

1 reference

12 December 2020

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

1 reference

12 December 2020

Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan

1 reference

12 December 2020

Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain

1 reference

12 December 2020

Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk--A Systematic Review and Meta-Analysis

1 reference

12 December 2020

The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis

1 reference

12 December 2020

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England

1 reference

12 December 2020

Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States

1 reference

12 December 2020

The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium

1 reference

12 December 2020

Corrigendum to "The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50years of age and older: A systematic review and meta-analysis" [Vaccine 34 (2016) 1540-1550]

1 reference

12 December 2020

Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network

1 reference

12 December 2020

Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13): An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

1 reference

12 December 2020

10.17269/S41997-018-0050-9

Identifiers

DOI

1 reference

1 July 2019

Dimensions Publication ID

0 references

1 reference

1 July 2019

PubMed publication ID

29981104

1 reference

1 July 2019